Recursion Pharmaceuticals Inc (RXRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.99B
Last updated: Nov 17, 2026 at 11:06 AM ET
Recursion Pharmaceuticals Inc (RXRX) Stock Forecast
Analysts expect Recursion Pharmaceuticals (RXRX) to earn -$0.88 per share in the fiscal year ending Dec 31, 2026, on revenue of $40.32M. Of 7 analysts, 3 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.29, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 43% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 28.6% |
| Buy | 1 | 14.3% |
| Hold | 4 | 57.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9.6%.
- Fiscal year ending Dec 31, 2026
- -$0.88
- EPS consensus, revenue $40.32M
- Fiscal year ending Dec 31, 2027
- -$0.83
- EPS consensus, revenue $44.20M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.88 | -$0.93 to -$0.76 | 8 | $40.32M | $36.19M to $45.00M | 7 |
| Dec 31, 2027 | -$0.83 | -$0.96 to -$0.68 | 7 | $44.20M | $10.00M to $87.82M | 8 |
Quarterly Estimates
The EPS consensus rises from -$0.22 for the quarter ending Dec 31, 2026 to -$0.19 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.23 to -$0.21 | 9 | $14.24M | $5.59M to $31.92M | 9 |
| Mar 31, 2027 | -$0.19 | -$0.21 to -$0.17 | 4 | $5.90M | $2.50M to $9.00M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.98.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.88 | -$0.93 | -$0.93 | -$0.92 | -$0.98 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.83 | -$0.87 | -$0.90 | -$0.89 | -$0.95 | N/A |
| Quarter ending Mar 31, 2027 | -$0.19 | -$0.22 | -$0.24 | -$0.24 | -$0.23 | N/A |
Frequently Asked Questions About RXRX
What is the RXRX stock forecast?
Consensus analyst estimates put Recursion Pharmaceuticals's EPS at -$0.88 for the fiscal year ending Dec 31, 2026, on revenue of $40.32M. The consensus rating from 7 analysts is Buy.
How do analysts rate RXRX stock?
Of 7 analysts covering Recursion Pharmaceuticals, 2 rate it Strong Buy, 1 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from RXRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.88, with estimates from -$0.93 to -$0.76 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.83, with estimates from -$0.96 to -$0.68 from 7 analysts.
What revenue do analysts expect from Recursion Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $40.32M, with estimates from $36.19M to $45.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $44.20M, with estimates from $10.00M to $87.82M.
How many analysts cover RXRX?
7 analysts rate Recursion Pharmaceuticals stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
RXRX pages: Overview, Earnings, Forecast, Financials, Competitors